Hoffmann SC. A new transgenic rat model overexpressing the angiotensin II type 2 receptor provides evidence for inhibition of cell proliferation in the outer adrenal cortex. Am J Physiol Endocrinol Metab 302: E1044 -E1054, 2012. First published February 7, 2012 doi:10.1152/ajpendo.00080.2011.-This study aimed to elucidate the role of the AT 2 receptor (AT2R), which is expressed and upregulated in the adrenal zona glomerulosa (ZG) under conditions of increased aldosterone production. We developed a novel transgenic rat (TGR; TGRCXmAT 2R) that overexpresses the AT2R in the adrenal gland, heart, kidney, brain, skeletal muscle, testes, lung, spleen, aorta, and vein. As a consequence the total angiotensin II (Ang II) binding sites increased 7.8-fold in the kidney, 25-fold in the heart, and twofold in the adrenals. The AT2R number amounted to 82-98% of total Ang II binding sites. In the ZG of TGRCXmAT2R, the AT2R density was elevated threefold relative to wild-type (WT) littermates, whereas AT1R density remained unchanged. TGRCXmAT2R rats were viable and exhibited normal reproduction, blood pressure, and kidney function. Notably, a slightly but significantly reduced body weight and a moderate increase in plasma urea were observed. With respect to adrenal function, 24-h urinary and plasma aldosterone concentrations were unaffected in TGRCXmAT2R at baseline. Three and 14 days of Ang II infusion (300 ng·min Ϫ1 ·kg Ϫ1 ) increased plasma aldosterone levels in WT and in TGR. These changes were completely abolished by the AT1R blocker losartan. Of note, glomerulosa cell proliferation, as indicated by the number of Ki-67-positive glomerulosa cells, was stimulated by Ang II in TGR and WT rats; however, this increase was significantly attenuated in TGR overexpressing the AT2R. In conclusion, AT2R in the adrenal ZG inhibits Ang II-induced cell proliferation but has no obvious lasting effect on the regulation of the aldosterone production at the investigated stages. zona glomerulosa; aldosterone production ANGIOTENSIN II (Ang II) plays a key role in cardiovascular homeostasis and stimulates aldosterone production. Ang II acts through different Ang II receptors such as the AT 1 (AT 1 R) and AT 2 receptors (AT 2 R). AT 1 R is the predominant Ang II receptor in adults and mediates the classic Ang II effects; AT 2 R is expressed abundantly in the fetus. In the adult, AT 2 R expression is limited to a few tissues such as brain, ovary, and adrenal gland but increases in vessels or the heart under pathological conditions; a physiological function is suggested (22, 30, 32) .
zona glomerulosa; aldosterone production ANGIOTENSIN II (Ang II) plays a key role in cardiovascular homeostasis and stimulates aldosterone production. Ang II acts through different Ang II receptors such as the AT 1 (AT 1 R) and AT 2 receptors (AT 2 R). AT 1 R is the predominant Ang II receptor in adults and mediates the classic Ang II effects; AT 2 R is expressed abundantly in the fetus. In the adult, AT 2 R expression is limited to a few tissues such as brain, ovary, and adrenal gland but increases in vessels or the heart under pathological conditions; a physiological function is suggested (22, 30, 32) .
The elucidation of the AT 2 R actions is complicated due to the low degree of AT 2 R expression in the adult (18, 45) . Thus, in contrast to AT 1 R, the functions and signaling mechanisms of AT 2 R remain elusive, and existing data are conflicting. AT 2 R has been shown to counterbalance AT 1 R functions (17, 52) ; however, under certain conditions AT 1 R and AT 2 R appear to transmit similar effects (47, 48) . AT 2 R may be activated particularly under pharmacological AT 1 R inhibition, because under this condition Ang II levels increase markedly (56) . The recent development of genetically engineered mouse models that either lack (6, 11) or specifically overexpress AT 2 R in the heart (21, 57, 58) or vascular smooth muscle (27, 55) provides a major step toward understanding AT 2 R function in these organs. However, models overexpressing AT 2 R in the adrenal gland, kidney, or brain are not yet available. Therefore, one aim of this study was to generate transgenic rats that overexpress AT 2 R in the adrenal gland, kidney, or brain during adulthood, allowing us to study tissue-specific AT 2 R effects and signal transduction pathways.
The adrenal gland is one of the few tissues in which AT 2 R expression persists into adulthood (for review, see Ref. 51) . So far it is still quite unclear whether or not the AT 2 R is involved in the regulation of adrenal function. Ang II is one major regulator of aldosterone synthesis in the zona glomerulosa (ZG) acting via the AT 1 R (1, 4, 5) . It is supposed that the AT 1 R is prevalent in adrenal cortex, whereas the AT 2 R dominates in adrenal medulla and contributes to the regulation of catecholamine synthesis (3, 5) . However, we recently found AT 2 R expression in the ZG and demonstrated its upregulation following stimulation of aldosterone synthesis by bilateral nephrectomy (37) or a high-potassium diet (Peters B, personal communication) . Furthermore, recent reports suggest an AngII effect on cortisol production via the AT 2 R in the zona fasciculata (ZF) in pigs (7) . The functional importance of AT 2 R expression in the ZG and in ZF remains as yet elusive. Thus, another aim was to test the hypothesis that AT 2 R overexpressed in the adrenal cortex regulates aldosterone and/or corticosterone synthesis.
MATERIALS AND METHODS
Generation of transgenic rats. A 1.54-kb XbaI fragment of mouse AT 2R genomic DNA containing 170 bp of the second intron and 1.37 kb of the third exon comprising the entire AT 2R coding region (kind gift of Prof. Tadashi Inagami) was placed between the 1.60-kb hybrid CX promoter [composed of the cytomegalovirus enhancer and the Ϫ276-to ϩ969-bp region of the chicken ␤-actin promoter (2, 16)] and the rabbit ␤-globin polyadenylation signal (Fig. 1A) . The 3.80-kb transgene was excised from the vector using SalI and HindIII, gel purified, and microinjected into the pronuclei of fertilized oocytes of Sprague-Dawley rats, as described previously (12) , to generate transgenic rats (TGR; TGRCXmAT 2R). Genotyping was performed by Southern blotting of EcoRI-digested tail DNA using a 32 P-labeled 1.2-kb ApaI fragment of the transgenic construct as a probe and by PCR using sense and antisense PCR primers designed from the third exon of the mAT 2R gene (5=GAGGCCCACACAAATGATCT3=) and the rabbit ␤-globin gene sequences (5=GGGCATATGTTGCCAA-ACTC3=).
RNA analysis by Northern blotting and real-time RT-PCR. Total RNA was extracted from snap-frozen heart, kidney, brain, adrenal gland, muscle, spleen, liver, lung, testes, aorta, vein, and thymus by means of guanidium isothiocyanate-cesium chloride centrifugation (TRIzol reagent; Life Technologies), fractionated on a 1% formaldehyde-agarose gel, and transferred to nylon membranes. Blots were hybridized with a specific, random-primer, 32 P-labeled DNA probe consisting of a 1.2-kb ApaI fragment of the transgenic construct, as described previously (14) . Rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels were used as loading standard. For Real-Time RT-PCR of promyelocytic leukemia zinc finger (PLZF) and GAPDH as internal control, RNA was treated with RNase-free DNase I (Qiagen), cleaned up with RNeasy spin columns (Qiagen), and reverse transcribed using M-MLV Reverse Transcriptase (Invitrogen). PCR was performed on a Light Cycler (Roche Diagnostics) using the QuantiTect SYBR Green PCR Kit (Qiagen), following the manufacturers' instructions in triplicate with the following primers : PLZF forward 5=-TTCATCCAGAGGGAGCTGTT-3=, reverse   5=-ACCGTTTTCCACAGAGTTCG-3=; and GAPDH forward 5=-TGC ACC ACC AAC TGC TTA-3=, reverse 5=-GGA TGC AGG  GAT GAT GTT C-3=. The amplification was performed with the  following time course: 15 min, 95°C, and 40 cycles of 95°C (denaturation) , 60 s; 55°C (annealing), 25 s, and 72°C (extension), 25 s. This was then followed by melting curve determination, 65°C for 15 s, and cooling, 40°C for 30 s.
Nonradioactive in situ hybridization. Nonradioactive in situ hybridization was performed to detect transgenic mAT 2R mRNA, as described previously (36) . A transgenic mAT2R transcript-specific probe was generated by PCR using the same primers as utilized for genotyping (as described above). The amplified 573-bp transcript corresponds to 195 bp of the mAT 2R gene and to 387 bp of the rabbit ␤-globin gene sequences. DIG1-11-UTP-labeled sense and antisense riboprobes were synthesized from the linearized plasmids using T3 and T7 RNA polymerases, respectively. In situ hybridization was carried out on 7-m-thick cryostat sections. The specificity of the in situ hybridization signal was verified by parallel incubation of antisense riboprobes on tissues of transgenic and nontransgenic animals. In situ hybridization for endogenous rat AT 2R transcripts was performed as described previously (37) .
Membrane preparation and binding assays. Membrane fractions were prepared from snap-frozen heart, kidney, adrenal gland, and adrenal capsules containing the ZG, as described previously (12) . Subcapsular tissue with ZG was manually separated from the inner tissue, as described previously (36) , resulting in contamination with ZF Ͻ5% (10). Adrenal capsules of two rats were pooled. Binding assay was performed as described elsewhere (13, 53) . Briefly, mem- Ci/mmol; DuPont-NEN) in a total assay volume of 200 l for 90 min at 22°C. Specific binding was determined from the differences between counts in the absence and presence of 10 mol/l unlabeled Ang II, 10 mol/l of a nonpeptide antagonist of the AT 2R PD 123319 (Sigma, München, Germany), and 10 mol/l of the AT 1R-specific nonpeptide antagonist CV 11974 (Alseda Pharmaceutical Industries, Osaka, Japan). All assays were run in duplicate.
Immunohistological staining for Ki-67. Proliferating cells were stained with an antibody against rat Ki-67 immunohistochemically, as described previously (29) . Briefly, deparaffinized sections were treated with 0.3% hydrogen peroxide, microwaved for antigen retrieval (20 min, 10 mM citrate buffer, pH 6.0 -6.2), and blocked with 2% BSA-1ϫ PBS for 1 h. The slides were incubated with anti-Ki-67 antibody (rat Ki-67, 1:50; Dako) for 1 h and then with a biotinylated secondary antibody (anti-mouse IgG, 1:200; Sigma). Incubation with avidin-biotin complex (ABC) reagent and colorimetric detection was accomplished according to the manufacturers' instructions (Vectastain Elite ABC-Peroxidase Kit, DAB Substrate Kit; Vector Laboratories). Proliferating cells were counted in 15 visual fields using a ϫ40 objective.
Animal experiments. All animal experiments were conducted in accordance with federal and local laws and institutional regulations and were approved by the Regierungspräsidium Karlsruhe, Land Baden-Württemberg. Sprague-Dawley rats were derived from a commercial source (Janvier). The generated transgenic lines and their wild-type (WT) littermates were bred and kept in our own animal facility at the Medical Faculty Mannheim. The rats were kept on a 12:12-h light-dark cycle with 55% humidity at an ambient temperature of 23 Ϯ 2°C and had free access to a standard pellet diet (Ssniff, Ferdinand-Gabriel-Weg 16, D-59494 Soest) and tap water. Ten-weekold male TGRCXmAT 2R line 199 (n ϭ 10), line 235 (n ϭ 12), and age-matched WT littermates (line 199, n ϭ 14; line 235, n ϭ 8) were used to determine body weight, heart, and kidney weights, and biochemical parameters from blood plasma. Creatinine and urea clearance were calculated using 24-h urine specimens collected from rats placed in metabolic cages. The same parameters, as well as blood pressure, were obtained from 9-to 11-mo-old male TGRCXmAT2R (line 199, n ϭ 12; line 235, n ϭ 8) and age-matched WT rats (n ϭ 7). Furthermore, rats were treated with either 300 ng Ang II·min Ϫ1 ·kg
Ϫ1
for 3 (experiment A) and 14 days (experiment B) or 300 ng Ang II·min Ϫ1 ·kg Ϫ1 plus 50 mg·kg Ϫ1 ·day Ϫ1 AT1R antagonist losartan (85530 Haar; LORZAAR-MSD Chibropharm) for 14 days (experiment C). Ang II and vehicle (isotonic saline) were applied via subcutaneously implanted osmotic minipumps (Alzet, type 2002). Losartan was given 9 days prior to and during the Ang II infusion with the drinking water. The following rats were used: 1) 12-wk-old male rats: Ang II, TGRCXmAT2R (line 199, n ϭ 4; line 235, n ϭ 7) and the respective WT littermates (line 199, n ϭ 3; line 235, n ϭ 7); vehicle, TGRCXmAT2R (line 199, n ϭ 5; line, 235 n ϭ 10) and WT (line 199, n ϭ 5; line 235, n ϭ 7); 2) 9-wk-old male rats: Ang II, TGRCXmAT2R/235 (n ϭ 6), and Sprague-Dawley rats (WT; n ϭ 6); baseline, TGRCXmAT2R/235 (n ϭ 6) and WT (n ϭ 6); 3) Ang II plus losartan: 9-wk-old male TGRCXmAT2R/235 (n ϭ 5) and WT littermates (n ϭ 8); vehicle, TGRCXmAT2R/235 (n ϭ 5) and WT littermates (n ϭ 8). Blood samples were taken before the start of Ang II infusion and at the end of Ang II treatment. Thereafter, animals were euthanized, and tissues were subdivided and either immersed in 0.2% paraformaldehyde in PBS, pH 7.4, for 2-4 h before being embedded in paraffin or snap-frozen in liquid nitrogen and stored at Ϫ80°C.
Plasma and serum parameters. Blood was collected from the retroorbital plexus of anesthetized (isoflurane) animals; the concentrations of urea, creatinine [enzymatic method (19) ], cholesterol, triglycerides, potassium, sodium, phosphate, and protein were determined on a Hitachi 911 (Roche Diagnostics, Mannheim, Germany). Renin concentrations were measured from EDTA-plasma enzymatically by its capacity to generate Ang I from excess renin substrate. Ang I was determined using a radioimmunoassay (RIA), as described previously (38, 39) . Plasma aldosterone and corticosterone levels were determined using a commercially available assay (DPC Biermann, Bad Nauheim, Germany). Aldosterone in urine was measured by a specific in-house RIA established at the Steroid Laboratory of the Department of Pharmacology, as described elsewhere (39) . Prior to RIA, a recovery-corrected extraction and a chromatographic purification were performed. Intra-and interassay coefficients of variation were Ͻ10 and Ͻ15%, respectively. Serum sodium and potassium were measured by flame photometry.
Blood pressure. Noninvasive tail-cuff pressures were measured at baseline in the conscious state in 9-to 11-mo-old male rats. Nontransgenic littermates of line 199 and 235 were used as WT (WT, n ϭ 7; TGRCXmAT2R/235, n ϭ 8; and TGRCXmAT2R/199, n ϭ 12). Rats were trained for 5 consecutive days; measurements were performed for 3 consecutive days. In addition, systolic blood pressure was measured on 4 consecutive days in freely moving 3-mo-old male rats (TGRCXmAT 2R/235, n ϭ 4; WT littermates, n ϭ 3) via a catheter (PE 0.4 mm) cannulated into the left aorta femoralis. Blood pressure was taken for 5 min at baseline and for 5 min following a bolus injection of 5 ng of Ang II in a 100-l volume via a second catheter (PE 0.58) that was implanted into the left vena femoralis. The catheters were tethered and protected using a rodent jacket, and the rats were kept in a Raturn Sampling Cage.
Statistical analysis. Data are expressed as means Ϯ SD or as median (25th/75th percentile). Differences between TGRCXmAT 2R and WT animals were analyzed by the unpaired sampled t-test or ANOVA, followed by Bonferroni correction for multiple comparisons; P Ͻ 0.05 was considered statistically significant. Saturation isotherms and the Scatchard plots were generated, and K d and maximum binding capacity (Bmax) were estimated by nonlinear regression using the InPlot program (GraphPad Software for Science; GraphPad, San Diego, CA).
RESULTS

Generation of transgenic rats that overexpress AT 2 R.
Four transgenic TGRCXmAT 2 R lines (199, 215, 235, and 238) harboring the mAT 2 R under the control of the CX promoter (Fig. 1A) were generated. Northern blotting revealed transgene expression in numerous tissues, with high levels in adrenal gland, lung, kidney, brain, skeletal muscle, blood vessels, and heart and testes (Fig. 1B) . Further studies were conducted using TGRCXmAT 2 R lines 199 and 235 with the highest transgene expression. Figure 2A shows the Ang II receptor densities in the heart, kidney, and adrenal glands of 8-to 10-wk-old male rats. In WT, the highest Ang II receptor density was found in the adrenal glands, followed by the kidney, whereas Ang II receptor density in the heart was very low. TGRCXmAT 2 R (lines 199 and 235) demonstrated a marked increase in B max in all tissues tested: in the kidney, 7.9-and 6.5-fold; in the adrenal gland, 2.0-and 1.9-fold; and in the heart, 14-and 22-fold, respectively, vs. WT ( Fig. 2A) . Affinities (K d ) were not changed significantly and agreed with previously published data (42) . Consequently, the proportions of AT 2 R relative to AT 1 R densities were increased markedly in TGRCXmAT 2 R rats, as demonstrated by competitive binding studies (Fig. 2B) . Transgene expression was detected in newborn rats and persisted at high levels Յ15 mo of age as assessed by Northern blotting and saturation binding studies (data not shown). Thus, the AT 2 R is the predominant Ang II receptor in cardiovascularrelevant tissues in adult TGRCXmAT 2 R but not WT rats. Assuming that the observed Ang II action is the net effect of activity at AT 1 R and AT 2 R, in TGRCXmAT 2 R we would expect to see a blunting of those AT 1 R-mediated effects that are opposed by AT 2 R and an enhancement of those Ang II effects that is based on concerted actions of AT 1 R and AT 2 R.
General characterization of TGRCXmAT 2 R. TGRCXmAT 2 R exhibited normal reproduction and development, and there was no evidence of compromised lifespan. Mean systolic baseline blood pressure did not differ between TGR and WT littermates, and it did not matter whether it was measured in 9-to 11-mo-old conscious rats by tail-cuff plethysmography [TGRCXmAT 2 R line 199, 150 Ϯ 14 mmHg; line 235, 147 Ϯ 10 mmHg; WT (line 199 ϩ 235), 144 Ϯ 8 mmHg] or in awake, freely moving, 3-mo-old rats via a catheter cannulated into the left aorta femoralis. Bolus injection of Ang II challenged a similar blood pressure response in TGRCXmAT 2 R and WT rats (Fig. 3) .
No gross morphological or histological alterations in the kidney, heart, or adrenal gland were observed (data not shown), and heart and kidney growth expressed as organ-tobody weight ratio was unaltered in TGRCXmAT 2 R (Table 1) . Notably, transgenic animals displayed a moderately lower body weight and a significantly increased plasma urea concentration and plasma urea/creatinine ratio relative to their WT littermates at the ages of 10 wk (Table 1) (Table 1) .
Transgenic mAT 2 R is expressed in the adrenal ZG. Transgene expression in the adrenal glands was studied in more detail. In situ hybridization revealed that WT rats express endogenous AT 2 R in the ZG and medulla (Fig. 4A) . Using the same probe, we found more intense staining in the adrenal cortex of TGRCXmAT 2 R because the rat AT 2 R probe cross- reacted with the transgenic AT 2 R, as shown in Fig. 4B . The transgene-specific AT 2 R probe did not cross-react with endogenous AT 2 R, as seen in WT samples (Fig. 4C) . In TGRCXmAT 2 R samples, intense signals for the transgenic AT 2 R were found in the whole adrenal cortex, including the cells of the ZG and the ZF (Fig. 4D) .
Next, we estimated the number of AT 1 R and AT 2 R binding sites in the total adrenal gland (Fig. 5, A and B) and in the capsules containing the ZG (Fig. 5, C and D ences in AT 1 R density between TGRCXmAT 2 R line 199, line 235, and WT (Fig. 5, A and B) . The adrenal levels of endogenous AT 2 R, AT 1 R, ACE1, ACE2, and angiotensinogen mRNA, as assessed by real-time PCR, were not modified by overexpression of transgenic AT 2 R mRNA (data not shown). Figure 5C shows the AT 1 R and AT 2 R densities in the adrenal capsule containing the ZG. In WT, Ang II binding in ZG was fourfold higher than in the whole adrenal glands, but the proportion of AT 2 R was somewhat lower (25 Ϯ 3.7%). AT 1 R binding sites in the ZG did not differ between TGRCXmAT 2 R and WT, but the number of AT 2 R binding sites was increased significantly 3.1-fold in TGRCXmAT 2 R/ 235 and 2.6-fold in TGRCXmAT 2 R/199 relative to WT; consequently, the AT 2 R/AT 1 R ratio increased 2.7-and twofold, respectively (Fig. 5, C and D) . The saturation-binding curves for AT 1 R and AT 2 R in the ZG from TGRCXmAT 2 R and WT rats are shown in Fig. 5 , E and F, respectively.
Effect of AT 2 R overexpression in the outer adrenal cortex on aldosterone levels and Ang II-induced proliferation.
Basal plasma aldosterone and renin levels ( Table 2) It is well accepted that Ang II stimulates aldosterone production and hyperplasia of ZG cells via the AT 1 R (26). To investigate a possible implication of the AT 2 R, we continuously infused Ang II (300 ng·kg body wt Ϫ1 ·day Ϫ1 ) for 3 days into TGRCXmAT 2 R/199 and TGRCXmAT 2 R/235 and their respective WT littermates and for 14 days into TGRCXmAT 2 R/235 and Sprague-Dawley rats as WT controls. As expected, plasma renin levels became markedly suppressed by Ang II (Table 2) so that the plasma Ang II was determined exclusively by the Ang II infusion. In all TGR and WT rats, the number of Ki-67-positive cells increased in the ZG and in the zone between ZG and ZF after 3 as well as after 14 days of Ang II stimulation, as expected (Fig. 6, A and D-H) . Remarkably, this proliferative response was significantly attenuated in the TGR at both stages. Also, the plasma aldosterone levels in TGR and WT increased in response to Ang II. After 3 days of Ang II infusion, the aldosterone levels varied considerably between the rats within a group, reflecting an early stage of stimulation (Table 2 and Fig. 6B, left) . Fourteen days of Ang II infusion evoked a striking raise in aldosterone levels up to Ͼ2,000 pg/ml in all TGR and WT rats (Table 2 and Fig. 6B, right) . Interestingly, the increases in plasma aldosterone were blunted in TGR of both lines at 3 days of Ang II infusion, although these differences reached statistical significance in only one line. After 14 days of Ang II infusion, the aldosterone response in terms of factor of stimulation did not differ between TGR and WT (18 Ϯ 10-fold in TGR vs. 25 Ϯ 15-fold in WT), although the absolute aldosterone levels were significantly higher in TGR. We would like to stress here that the factor of stimulation is more meaningful than the absolute aldosterone levels. Unlike all the other experiments performed in this study, in the 14-day Ang II stimulation experiment, SpragueDawley rats in place of nontransgenic littermates were used as WT controls. In the course of breeding, WT littermates of TGRCXmAT 2 R, originally generated on a Sprague-Dawley background, turned out to have higher baseline plasma aldosterone levels than Sprague-Dawley rats obtained from external sources (Table 2 and Fig. 6B, right) . This difference reflects changes only in the genetic background.
Of note, the AT 1 R antagonist losartan completely abolished the aldosterone response in both TGRCXmAT 2 R/235 and WT rats ( Table 2 ). As anticipated, the losartan-induced increase in plasma renin levels was similar in TGR and WT rats even during Ang II infusion.
Previous studies identified the antiproliferative-acting and growth-promoting PLZF (43, 46, 59) as a novel direct interaction partner of the AT 2 R that, for example, mediates the hypertrophic action of the AT 2 R in the heart (44). To evaluate whether PLZF, which is downregulated after birth in many organs except for the heart, may have a potential role in AT 2 R actions in adrenals, we determined PLZF mRNA levels in adult adrenals compared with heart and kidney. We found the highest PLZF expression in the adrenals (Fig. 6C) .
Corticosterone production or corticosterone response to Ang II is not altered by increased AT 2 R in ZG. The transgenic AT 2 R was expressed in the ZF, which produces the major glucocorticoid (in the rat, corticosterone). We measured plasma corticosterone levels to evaluate a possible effect of AT 2 R on corticosterone production. Corticosterone levels at baseline and following Ang II stimulation in TGR were not different from WT (Table 2) . Thus, Ang II elicited the expected response (e.g., stimulation of corticosterone production), but this effect is rather mediated by the AT 1 R and not by the AT 2 R.
DISCUSSION
We report the generation of a new transgenic rat model that overexpresses the mAT 2 R in kidney, heart, brain, aorta, vein, testes, and adrenal gland throughout life.
Currently, few data are available concerning the role of AT 2 R in the adult (24, 34) . The elucidation of the AT 2 Rrelated actions is complicated, since the AT 2 R effects and signal transduction are largely contextual and the AT 1 R predominates over the AT 2 R. Thus, this novel TGRCXmAT 2 R rat model provides a tool to investigate the pathophysiological role and the signal transduction mechanisms of AT 2 R in adults.
We did not detect obvious functional and structural disturbances in the TGRCXmAT 2 R, although the AT 2 R/AT 1 R ratio increased dramatically in many tissues throughout life. We focused particularly on the role of AT 2 R in the adrenal ZG because the adult ZG exhibits a considerable number of AT 2 R in the physiological function, which has so far been unappreciated. Furthermore, the regulation of aldosterone production has recently acquired importance due to pathological implication of inappropriate aldosterone secretion and its direct link to cardiac fibrosis and hypertrophy (8, 60) . We provide evidence that AT 2 R overexpression in adrenal ZG inhibits the rise in cell proliferation following Ang II stimulation for 3 and 14 days. Aldosterone response to Ang II seems to be delayed in TGR but has remained unchanged in the long run.
To drive transgene expression, we used the CX promoter that was developed originally to be a strong promoter for the pCAGGS expression vector and has utilized features of the cytoplasmic ␤-actin promoter, which is highly active in a wide range of cell types (25, 33) . The transgenic AT 2 R is highly expressed in important tissues and causes a shift from AT 1 R to AT 2 R predominance. This is particularly obvious in the kidney and heart, which express AT 2 R at negligible levels in WT animals. Importantly, the absolute numbers of AT 1 R are unaffected by the transgene expression. The Ang II effect is assumed to be determined by the ratio of AT 1 R/AT 2 R, although both receptors often mediate antagonistic actions (20) . Interestingly, the prevalence of the AT 2 R did not cause obvious developmental abnormalities or morphological and histological alterations, indicating that the AT 2 R excess has no detrimental effects. Mouse models with AT 2 R deficiency (6, 15) or tissue-specific overexpression (21, 55) were also not affected by reduced survival or lifespan. The development of cardiac failure in a transgenic mouse line with ventricular overexpression of AT 2 R was related to the level of transgene expression. Whereas a line with a AT 2 R density of B max ϭ 884 fmol/mg protein developed cardiac disease, a second line with slightly lower transgene expression (B max ϭ 706 fmol/mg protein) was healthy (57) . In our TGRCXmAT 2 R the cardiac density of AT 2 R was even lower (B max ϭ 302 fmol/mg protein), which might explain the lack of phenotype in the heart. Although we found AT 2 R to be expressed in blood vessels, the transgenic rats were normotensive and exhibited a largely similar pressure response to Ang II as WT rats. This seems to be in contrast to previous studies describing an enhanced vasoconstrictive effect of Ang II in AT 2 R-knockout mice (11, 15) or a vasodilatation due to AT 2 R overexpression in vascular smooth muscle cells (55) . However, even in these models no or only minor changes in baseline blood pressure were found. Unlike these models, in our TGRCXmAT 2 R the transgenic receptor driven by the CX promoter is not expressed essentially in each cell, and the expression levels vary between tissues. Consequently, we did not inevitably expect a modification in systemic blood pressure. Thus, any differences between the studies may still be explained by degree and specific site of AT 2 R overexpression in the vessels. Ongoing studies will elucidate the role of the transgenic AT 2 R in the heart, kidney, and circulation under challenged and pathological conditions that are more detailed.
Notably, in all four TGRCXmAT 2 R lines, plasma urea/ creatinine ratios were enhanced as a consequence of elevated plasma urea levels, whereas urinary urea excretion was unchanged, arguing against a filtration defect or modulated function of the urea transporter in the kidney. As reported previously, Ang II induces muscle wasting by stimulating the ubiquitin-proteasome pathway and apoptosis (49) . In our model the transgenic AT 2 R is highly overexpressed in skeletal muscle, and the body weights of TGR were reduced slightly compared with WT rats. These findings point to a possible involvement of the AT 2 R in Ang II-induced muscle wasting. Corticosterone involvement is unlikely because we did not find alterations in corticosterone levels in TGRCXmAT 2 R.
We demonstrated further that the adrenal glands, particularly the ZG, exhibited the highest AT 2 R density compared with other tissues in WT rats. Aldosterone production in ZG, tightly controlled by Ang II via the AT 1 R, was found to correlate with the AT 2 R transcript levels (37) , which suggests an involvement of AT 2 R in regulating aldosterone production. This assumption is also supported by Naruse et al. (28) , who found that aldosterone levels transiently decreased following AT 1 R antagonist treatment but returned to baseline over time (aldosterone escape phenomenon). Under these circumstances the AT 2 R expression was elevated and the aldosterone escape phenomenon prevented by combined treatment with AT 1 R and AT 2 R antagonists. However, studies by others concerning the role of AT 2 R in aldosterone production provided conflicting data (4, 23) , and an indirect AT 2 R action on aldosterone via catecholamine stimulation was speculated (25) .
Despite a roughly threefold increase in AT 2 R binding sites and in the AT 2 R/AT 1 R ratio in the ZG of TGRCXmAT 2 R relative to WT, the plasma aldosterone levels and aldosterone/ renin ratios at baseline were not altered. When challenged by Ang II for 3 and 14 days, plasma aldosterone levels as well as the number of Ki-67-positive ZG cells increased in both TGRCXmAT 2 R and WT. It has been well established that, in addition to regulating the steroidogenic function of the ZG, Ang II exerts mitogenic effects (24, 31, 54) . How this mitotic activity relates to the aldosterone production is not fully understood. Ang II stimulates aldosterone production of ZG cells via the AT 1 R by two main mechanisms: 1) by the depolarization of the cell membrane through inhibition of the Na-KATPase and of K ϩ channels such as the TWIK-related acidsensitive K ϩ channel and 2) by the induction of a potent Ca 2ϩ signal (50) , which might also be related to the cell cycle control. In this manner, Ang II evokes a rapid aldosterone response. In contrast, the AT 2 R causes hyperpolarization and repolarization of cell membranes by opening potassium channels in neuronal cells and vascular smooth muscle cells (9) . Thus, the AT 2 R might potentially antagonize the AT 1 R-mediated aldosterone increase. However, the glomerulosa cells are functionally an inhomogeneous cell population. Only part of them is enabled to produce aldosterone. Thus, in addition to increasing the aldosterone production per cell as a rapid response, Ang II stimulates the aldosterone production by increasing the absolute number of aldosterone-producing cells. This is accomplished by enhancing cell proliferation and/or by a recruitment of steroidogenic inactive cells to aldosterone production (31, 37, 50) . Remarkably, the AT 2 R overexpression in TGRCXmAT 2 R significantly attenuated the Ang II stimulation of glomerulosa cell proliferation, but the aldosterone production was, if ever, only transiently blunted. The antimitotic effects of the AT 2 R have been demonstrated previously in distinct tissues like vascular neointima and coronary endothelial cells (44, 52) . Furthermore, studies indicate that Ang II exerts a mitotic action through the AT 1 R only if the AT 2 R is absent (52) . Otis et al. (34) demonstrated in vitro that the Ang II-promoting effect on protein synthesis occurs with a concomitant arrest in basal cell proliferation, suggesting a shift of pathways involved in proliferation to those involved in protein synthesis (34, 35) . This implies that hampered proliferation of ZG cells could go along with a rise in cells that differentiate and grow. We demonstrated in an earlier study that the elimination of circulating active renin by bilateral nephrectomy leads to increased AT 2 R expression in the ZG, but the number of proliferating ZG cells was lowered to even undetectable levels. Nonetheless, the number of aldosterone-producing cells as well as aldosterone production was increased markedly, which was explained by a recruitment/differentiation of steroidogenic inactive cells (37) . The assumption that AT 2 R in the ZG could play a role for differentiation can be strengthened by our data, but visualizing the precise mechanism needs further elucidation.
Putative signaling pathways involved in AT 2 R-mediated antiproliferative effects may imply a direct inhibition of AT 1 Rmediated signaling by dephosphorylating ERK1/2 via activation of the protein phosphatases SH2 domain-containing protein tyrosine phosphatase-1, protein phosphatase 2A, and MAPK phosphatase-1 or by a direct physical interaction (i.e., heterodimerization) with the AT 1 R (35, 40, 41) . Another possible mechanism may involve the novel AT 2 R-interacting transcription factor PLZF. Following Ang II stimulation, PLZF is activated, interacts physically with the AT 2 R, and then translocates to the nucleus, where it stimulates the phosphatidylinositol 3-kinase-p85␣ expression, leading to increased protein synthesis and cell growth (44) . Remarkably, in vitro and in vivo studies established an antiproliferative effect of PLZF in different cells and tissues, which seems to be mediated by the suppression of cyclin A and proproliferative genes (43, 46, 59) . PLZF, highly expressed in embryonic life, is downregulated in most adult organs but expressed considerably in the heart. Here, we demonstrate that PLZF is expressed robustly in the adrenal gland and thus could mediate AT 2 R effects on growth and differentiation. In such a case, despite limiting cell proliferation, AT 2 R could still affect the percentage of aldosteroneproducing cells by recruiting previously steroidogenic inactive cells to aldosterone production. The TGRCXmAT 2 may well represent a useful model to elucidate this complex regulatory network.
Notably, we furthermore did not find any effect of transgenic AT 2 R expression in the ZF on corticosterone production. We just observed an increase of corticosterone production by Ang II, as expected, but no effect of AT 2 R overexpression. AT 2 R expression was not found in the ZF of WT animals, suggesting that necessary components of the AT 2 R signaling network are absent in fasciculata cells. Furthermore, the absence of any effect of AT 2 R overexpression in the ZF implies that the previously observed Ang II-dependent increase in glucocorticoid production (7) is mediated by the AT 1 R.
In summary, we describe a novel transgenic rat model that overexpresses the AT 2 R in important cardiovascular tissues. This model is a powerful tool for analyzing the relevance and mechanisms of AT 2 R activity in the adult organism under both physiological and pathophysiological conditions. Moreover, this TGRCXmAT 2 R model is an excellent source for distinct AT 2 R-overexpressing cells and tissues for in vitro studies. Using this model, we demonstrate that AT 2 R overexpression in the adrenal ZG counteracts the AT 1 R-mediated proliferative response of ZG to Ang II and has minor effects on aldosterone production that may vary in the course of Ang II stimulation. We demonstrated further that AT 2 R overexpression in the ZF is functionless with regard to corticosterone production.
